Poly-ADP-ribose polymerase (PARP) inhibitors and ovarian function

Jiajia Li; Qingchao Li; Lingyi Zhang; Songling Zhang; Yun Dai

doi:10.1016/j.biopha.2022.114028

Poly-ADP-ribose polymerase (PARP) inhibitors and ovarian function

Biomed Pharmacother. 2023 Jan:157:114028. doi: 10.1016/j.biopha.2022.114028. Epub 2022 Nov 18.

Authors

Jiajia Li¹, Qingchao Li², Lingyi Zhang³, Songling Zhang⁴, Yun Dai⁵

Affiliations

¹ Gynecologic Oncology Department, First Hospital of Jilin University, Changchun, Jilin, China; Laboratory of Cancer Precision Medicine, First Hospital of Jilin University, Changchun, Jilin, China.
² Laboratory of Cancer Precision Medicine, First Hospital of Jilin University, Changchun, Jilin, China.
³ Laboratory of Cancer Precision Medicine, First Hospital of Jilin University, Changchun, Jilin, China; Gynecology and Obstetrics Department, Second Hospital of Jilin University, Changchun, Jilin, China.
⁴ Gynecologic Oncology Department, First Hospital of Jilin University, Changchun, Jilin, China. Electronic address: slzhang@jlu.edu.cn.
⁵ Laboratory of Cancer Precision Medicine, First Hospital of Jilin University, Changchun, Jilin, China. Electronic address: daiyun@jlu.edu.cn.

PMID: 36410122
DOI: 10.1016/j.biopha.2022.114028

Abstract

Poly-ADP-ribose polymerase (PARP) plays an important role in DNA damage detection and repair. PARP inhibitors (PARPi) are a novel class of targeted agents used widely in the treatment of female cancer patients with BRCA mutations, including younger patients. However, the impact of PARPi on ovarian function remains a considerable problem in clinical practice. In this review article, we summarize the current understanding of PARPi's effects on the function of ovary and discuss their potential underlying mechanisms, highlighting the significance of further investigation on the criterion for ovarian failure and its preventive approaches during PARPi treatment.

Keywords: BRCA mutation; DNA repair; Fertility; Ovarian function; PARP inhibitor.

Publication types

Review

MeSH terms

Adenosine Diphosphate Ribose / therapeutic use
DNA Damage
Female
Humans
Ovarian Neoplasms* / drug therapy
Ovarian Neoplasms* / genetics
Poly(ADP-ribose) Polymerase Inhibitors / pharmacology
Poly(ADP-ribose) Polymerase Inhibitors / therapeutic use
Poly(ADP-ribose) Polymerases* / genetics

Substances

Poly(ADP-ribose) Polymerases
Poly(ADP-ribose) Polymerase Inhibitors
Adenosine Diphosphate Ribose